Designing idiosyncratic hmPCL-siRNA nanoformulated capsules for silencing and cancer therapy

Vijay Bhooshon Kumar, Himadri Medhi, Zhang Yong, Pradip Paik

Research output: Contribution to journalArticlepeer-review

20 Scopus citations


In this work, we have designed a siRNA-nanoformulation with mesoporous polycaprolactone (hmPCL) for silencing and cancer therapy. Average hollow core size of hmPCL nanocapsules used for nanoformulation is ~ 180 nm with shell thickness of 10-20 nm and mesopore size of ~ 5-10 nm in diameter. Idiosyncratic capsules are biocompatible which has been confirmed with normal lymphocyte, K562 leukaemia cancer cells and on HepG2/EGFP cancer cells. In 1 mg of hmPCL capsules up to 400 ng of siRNA can be loaded. This nanoformulation enables to tune the dose dependent delivery up to ~ 93.25% (373 ng) siRNA during therapy. hmPCL-siRNA nanoformulation mediated siRNA transfection on HepG2 cancer cells has been investigated and exhibited 32% silencing activity within 24 h of post transfection. Obtained results directed us that the hmPCL-siRNA nanoformulation could be an efficient tool in siRNA mediated therapy for knocking down the infected cells.

Original languageEnglish
Pages (from-to)579-588
Number of pages10
JournalNanomedicine: Nanotechnology, Biology, and Medicine
Issue number3
StatePublished - 1 Apr 2016
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2015 Elsevier Inc.


  • Cancer therapy
  • Hollow-mesoporous-PCL
  • Nanocapsules
  • Nanoformulation
  • SiRNA-silencing


Dive into the research topics of 'Designing idiosyncratic hmPCL-siRNA nanoformulated capsules for silencing and cancer therapy'. Together they form a unique fingerprint.

Cite this